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Abstract
Background: Tramadol is an atypical centrally acting analgesic agent available as both oral and parenteral
preparations. For patients who are unable to take tramadol orally, the subcutaneous route of administration offers
an easy alternative to intravenous or intramuscular routes. This study aimed to characterise the absorption
pharmacokinetics of a single subcutaneous dose of tramadol in severely ill patients and in healthy subjects.
Methods/design: Blood samples (5 ml) taken at intervals from 2 minutes to 24 hours after a subcutaneous dose of
tramadol (50 mg) in 15 patients (13 male, two female) and eight healthy male subjects were assayed using high
performance liquid chromatography. Pharmacokinetic parameters were derived using a non-compartmental
approach.
Results: There were no statistically significant differences between the two groups in the following parameters
(mean ± SD): maximum venous concentration 0.44 ± 0.18 (patients) vs. 0.47 ± 0.13 (healthy volunteers) mcg/ml
(p = 0.67); area under the plasma concentration-time curve 177 ± 109 (patients) vs. 175 ± 75 (healthy volunteers)
mcg/ml*min (p = 0.96); time to maximum venous concentration 23.3 ± 2 (patients) vs. 20.6 ± 18.8 (healthy volunteers)
minutes (p = 0.73) and mean residence time 463 ± 233 (patients) vs. 466 ± 224 (healthy volunteers) minutes (p = 0.97).
Conclusions: The similar time to maximum venous concentration and mean residence time suggest similar absorption
rates between the two groups. These results indicate that the same dosing regimens for subcutaneous tramadol
administration may therefore be used in both healthy subjects and severely ill patients.
Trial registration: ACTRN12611001018909
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Background
Tramadol is an atypical centrally acting analgesic agent
available as both oral and parenteral preparations. If
given parenterally, the intravenous (IV) route is com-
monly preferred. However, administration of large IV
bolus doses of tramadol can result in a high incidence of
nausea and vomiting, which may be decreased by redu-
cing the rate of delivery or by administering the drug via
the subcutaneous (SC) route [1,2]. IV administration also
requires venous access which is associated with infective
and thromboembolic complications. Furthermore, while
the intramuscular (IM) route is another alternative, SC
delivery is preferred by patients [3,4]. A SC cannula can
be sited for repeated needleless injections, reducing pa-
tient discomfort and increasing patient and staff safety
[5]. Therefore, for patients who are unable to take tram-
adol orally, the SC route of administration offers an easy
alternative. Although the pharmacokinetic profile of tram-
adol has been previously characterised in humans after
oral, IM, IV administration, similar data are not available
for subcutaneous tramadol and cannot be extrapolated
from these studies [6-9].
While tramadol as the sole analgesic agent for the
management of moderate to severe acute pain may be
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inadequate, when used as part of a multimodal analgesic
regimen in severely ill and other patients it may offer
several advantages [10]. Compared with pure opioid
agonists at equianalgesic doses, tramadol is signifi-
cantly less likely to lead to respiratory depression and
has less effect on gastrointestinal motor function than
morphine, whilst nausea and vomiting are the most
common adverse effects and occur at rates similar to
other opioids [1,11-17].
It is important to understand the pharmacokinetics of
tramadol after SC injection, especially the rate of absorption
and time to peak blood concentration, to determine
the optimal dose and frequency of administration. It is
also necessary to determine if there are differences be-
tween healthy subjects and severely ill patients in order
to know if different dose regimens are needed in the
healthy postoperative patients and in the unstable pa-
tients in the high dependency area.
The aim of this study was therefore to evaluate the
pharmacokinetics of 50 mg tramadol administered as a
single SC bolus dose to healthy opioid-naïve subjects
and to severely ill patients in a high dependency setting.
Evaluating the absorption kinetics for tramadol in
healthy subjects and in patients will also assist in clinical
decision-making and a better understanding of whether
dosing regimens based on results from studies in healthy
subjects may be transferrable to patients.
Methods/design
Following approval from the Royal Adelaide Hospital
Human Research Ethics Committee (approval numbers:
patients - 90719; healthy subjects - 80717) and written
informed consent, eight healthy male subjects and fifteen
patients in the high dependency unit were enrolled in
the study which was conducted separately for healthy
subjects and patient in accordance with National Health
and Medical Research Council of Australia guidelines.
Healthy subjects
Healthy male subjects aged 18 to 65 years (inclusive)
were recruited by advertisement in the university com-
munity. Body weight was greater than 50 kg and body
mass index (BMI) was between 19 and 30 kg/m2. There
was a requirement for adequate venous access in the left
or right arm to allow collection of a number of blood
samples. Health status was ascertained a week prior to
the study by medical interview, physical examination
and laboratory investigations including haematology,
coagulation, biochemistry, liver function and urine drug
screen (DipScan, Point of Care Diagnostics Australia Pty
Ltd, Artarmon, NSW). All subjects were followed up one
week after the study, when they repeated the medical
interview and examination and reported any adverse
events following the study.
Patients
Patients from the high dependency unit in a tertiary referral
university hospital were considered for inclusion if they had
been admitted with moderate to severe pain following sur-
gery or trauma, were aged between 18 and 75 years of age,
and were receiving fentanyl by patient-controlled analgesia
(PCA) for management of their acute pain. All patients
underwent detailed workup including history, physical
examination and laboratory investigations including haema-
tology, coagulation, biochemistry, liver function and urine
drug screen (DipScan, Point of Care Diagnostics Australia
Pty Ltd, Artarmon, NSW). Reliable venous access in the left
or right arm was required to allow collection of a number
of blood samples.
Patients were given fentanyl by PCA because it is
metabolised by the cytochrome P450 enzymes CYP3A4/
5 and not CYP2D6, the latter being the main enzyme re-
sponsible for the metabolism of tramadol and produc-
tion of O-desmethyltramadol (M1), the active metabolite
of tramadol responsible for most of the drug’s opioid
agonist effect. Informed consent was obtained from the
patients the day before the study commenced.
Exclusion criteria
Exclusion criteria for both the healthy subjects and pa-
tients included an allergy or hypersensitivity to opi-
oids, current use of opioid or psychoactive medications
(including sedatives, hypnotics or tranquillisers), current
or previous alcohol or drug abuse, current or recent use
of medications or herbal preparations known to induce or
inhibit CYP2D6/CYP3A4 enzymes, renal impairment
(defined as a calculated creatinine clearance of ≤ 75 ml/min),
donation of blood within three months prior to the study,
or any condition that would interfere with blood sampling
or drug disposition [18].
Exclusion criteria also included abnormal liver func-
tion (in healthy subjects defined as outside the normal
laboratory range; in the patient group defined as liver
function tests > 3 times the upper limit of normal range).
Healthy subjects were also excluded if the urine drug
screen was positive for any opioids, benzodiazepines,
amphetamines, cocaine or cannabis.
Study design and procedures
Healthy cohort
A urine drug screen was performed on the morning be-
fore tramadol administration. An 18 gauge IV cannula
(Introcan, Braun, Germany) was placed in a forearm or
antecubital fossa vein for blood sampling. A 20 ml sam-
ple was withdrawn prior to tramadol (Tramal®, tramadol
hydrochloride [CSL Limited]) administration for assay
standards. Each subject received a single SC bolus dose
of 50 mg of tramadol injected over 60 seconds through a
27 gauge needle sited just inferior to the clavicle on the
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contralateral side to the cannula. The SC needle was
primed with tramadol prior to placement and the bolus
dose administered immediately upon insertion.
Blood samples (5 ml) were collected from the venous
cannula at 2, 5, 10, 15, 30, 60, 90, 120, 180, 240, 300,
360, 480, 600 minutes and 24 hours after tramadol dosing.
Urine was collected from 0 to 10 hours after the dose was
given so that tramadol, M1 and N-desmethyltramadol (M2)
concentrations could be measured.
Patients
The same protocol for tramadol administration and blood
sampling was followed as for the healthy subjects. Acute
Physiological and Chronic Health Evaluation (APACHE II)
scores were calculated on the day of the study. The
APACHE II score is a classification system designed to
assess the severity of disease for adult patients admitted
to an intensive care unit [19]. Urine was also collected
cumulatively for the first 10 hours of the study for
measurement of tramadol, M1 and M2 concentrations.
Monitoring
During the study period, all patients and healthy sub-
jects had respiratory and heart rates, sedation scores,
temperature and the severity of nausea/vomiting re-
corded every 30 minutes for the first 3 hours, and then
hourly for the duration of the study. Level of sedation
was scored on a 4-point scale from 0 to 3 (0 = wide
awake, 1 = rouses easily and can stay awake; 2 = rouses
easily but has difficulty staying awake, and 3 = somnolent,
difficult to rouse) [5]. The degree of nausea and vomiting/
retching was scored on a scale from 0 to 3 (0 = none,
1 = mild and does not need treatment, 2 = treatment
was effective, 3 = persists despite treatment). Peripheral
oxygen saturation (SpO2) levels and respiratory rates were
also monitored and the lowest values recorded. Any other
adverse effects reported by the patients and healthy sub-
jects were also documented.
Processing of blood samples
The blood samples were stored in 10 ml heparinised
plastic tubes and centrifuged within 2 hours of collection.
Following centrifugation, the plasma was transferred into
identically labeled polypropylene tubes. Samples were then
frozen at −20°C and transferred to a −70°C freezer within
24 hours of processing. The samples were later transferred
to the analytical laboratory and stored at −20°C for trama-
dol determination.
Plasma and urine assays
Plasma and urine tramadol, M1 and M2 concentrations
were determined by high-performance liquid chromatog-
raphy (HPLC) with fluorescence detection and using an
external standardisation procedure as no internal standard
was readily available at that time. This then required exact
volumes of all liquids as outlined below. Plasma sample
preparation was as follows: plasma (500 μl) was alkalinised
with 1 M (100 μl) sodium hydroxide prior to extraction in
3 ml hexane: ethyl acetate (80:20). The organic layer
(2.7 ml) was then back extracted into 0.05 M (150 μl)
hydrochloric acid, the organic phase was aspirated and
100 μl of the remaining acidic phase was injected on to
the HPLC system. Urine sample preparation was as fol-
lows: samples were centrifuged (6 minutes, 14000 r.p.m.),
the supernatant was diluted to 1 in 100 in mobile phase
(details below) and injected (100 μl) on to the HPLC
system. The retention time of tramadol was 5.4 minutes
(plasma) and in urine was 8.0 minutes and M1 and M2
metabolites were 3.7 and 8.7 minutes, respectively follow-
ing mobile phase modification. Peak areas were used as
output responses.
The HPLC system was a LC Workstation Class LC10
(Shimadzu, Kyoto, Japan) consisting of a SIL-10ADvp auto
injector and LC-10ADvp liquid chromatograph (pump),
with fluorescence detection (excitation and emission
wavelengths of 210 and 305 nm, respectively; LC-240
Perkin Elmer, Buckinghamshire, UK) and a C-R6A
Chromatopac integrator (Shimadzu, Kyoto, Japan).
Tramadol, M1 and M2 were separated on a C18 LUNA
analytical column (150 × 4.6 mm, Phenomenex, Lane Cove,
Australia). The mobile phase for urine samples consisted of
acetonitrile: 25 mM di-potassium hydrogen phosphate
(39:61, v/v) adjusted to pH 8.9 with 85% orthophosphoric
acid at a flow rate of 1.0 ml/min, and the mobile phase
for plasma samples consisted of acetonitrile: 25 mM
di-potassium hydrogen phosphate (15:75, v/v) adjusted
to pH 3.0 with 85% orthophosphoric acid at a flow rate
of 1.5 ml/min.
Calibration curves for tramadol, M1 and M2 quantifi-
cation from urine samples were constructed with 6 final
concentrations (ng/ml) ranging from 500 to 5000, 10
to 475 and 75 to 475, respectively. Calibration samples
were prepared identically in blank human urine. Low,
medium and high QC samples of tramadol, M1 and M2
were also prepared with final concentrations (ng/ml) of
750, 75 and 75, respectively; 2500, 250 and 250, respect-
ively; and 4750, 475 and 475, respectively. The inter-
and intra-assay imprecision and inaccuracy of the assays
(n = 6) based on the QC samples were all < 10%. At the
LLOQ of 25 ng/ml, intraday imprecision was 8.7% and
inaccuracy was 4.2%; at the low (75 ng/ml), medium
(200 ng/ml) and high (350 ng/ml) QCs, the values were
6.5% and 1.6%, 9.0% and 2.7% and 6.7% and 4.3%, re-
spectively (all n = 6). For interday imprecision and in-
accuracy, the values were 17.4% and 5.8%, 6.9% and
2.9%, 9.2% and 6.4% and 2.6% and 2.8% (n = 6). There
was no extraction required for the urine samples and
the recovery was >95%.
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Calibration curves for tramadol quantification from
plasma samples were constructed with 6 final concentra-
tions ranging from 25 to 1000 ng/ml. Calibration sam-
ples were prepared identically in blank human plasma.
Low, medium and high quality control (QC) samples of
tramadol were also prepared with final concentrations
(ng/ml) of 75, 200 and 350, respectively. Extraction re-
covery of tramadol was > 54.3%. The inter- and intra-
assay (n = 6) imprecision and inaccuracy of the assays
based on the QC analysis were all < 17.5%. The lower
limit of quantification was 25 ng/ml. The protocols in
both groups were exactly the same and blood samples
were collected up to 24 hours after tramadol dosing.
However, the curves were truncated because at certain
time points, the concentrations fell below the limit of
quantification (<LOQ) and were not easily detectable
using the assay described (Figure 1).
The assay in both plasma and urine from patient samples
revealed no additional peaks or shoulders on the chromato-
gram and chromatograms from other patient samples not
administered tramadol contained no peaks at the reten-
tion times. Plasma and urine samples stored at −20°C
for 3.6 and 9 months revealed no time-dependent changes
in concentration.
Non-compartmental analysis of pharmacokinetics
The data were analysed using a non-compartmental
approach (NCA) based on analysis of calculated and
extrapolated area under the curve (AUC0-∞) [20]. The
AUC from zero time to the last quantifiable concentration
was calculated by trapezoidal integration (linear up,
log down method) and extrapolated to time infinity by
assuming an exponential decline (best fit of 3 to 6 data
points) to estimate the terminal exponential rate constant
and therefore terminal half-life (t½). The analysis used pre-
viously validated scripts written in the R language [21].
Other pharmacokinetic parameters including time taken to
reach maximum plasma concentrations (tmax), maximum
plasma concentration (Cmax), t½ and mean residence time
(MRT) were also calculated from the observed data. Urine
concentrations of tramadol, M1 and M2 metabolites and
total urine volume were used to calculate the total amount
of each excreted in 10 hours.
Statistical analysis
Demographic data are expressed as median (range)
and were analysed using a two-tailed unpaired t-test.
Pharmacokinetic data analysis used the R data analysis and
statistical language (Version 2.10.1) using a single factor
ANOVA [21]. Values were expressed as mean (±SD), or as
mean (range) depending on their distribution.
Results
The study was completed safely with no tramadol-related
adverse effects reported in either group. Of the 10 healthy
subjects recruited, two did not attend on the designated
study day and the two reserves were also unavailable,
hence eight were studied. Two of the patients were given
a single dose of oxycodone during the study period. Their
data were not excluded from analysis as oxycodone does
not inhibit CYP2D6 (see discussion).
The demographics of the two study groups are sum-
marised in Table 1. All the eight subjects in the healthy
cohort were male: median age 25 years (range 19 to 51),
Figure 1 Individual plasma tramadol concentrations in the healthy subjects and patients. All patients and healthy subjects received a 50 mg
subcutaneous bolus dose of tramadol. The median for each subject group is shown by the solid line. Graphs are truncated at 1200 minutes and
1440 minutes respectively, as plasma concentrations were less than the lower limit of quantification of the assay.
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median weight 74 kg (range 60 to 97). The median age
of the 15 patients (13 male and two female) was 43 years
(range 20 to 65), median weight was 75 kg (range 72 to 76)
and median Acute Physiological and Chronic Health
Evaluation II score was 7 (range 2 to 14). The healthy group
was significantly younger than the patients (p = 0.006).
There was no difference in weight between the two groups.
Diagnoses included 10 patients with multi-trauma, one
patient who underwent orthopedic surgery and four
patients who had gastrointestinal surgery.
No abnormalities were detected in any investigations
performed at either the pre-study or post-study screen-
ing. None of the healthy subjects or patients showed
clinically significant changes in blood pressure, SpO2
levels, heart rate, respiratory rate or body temperature
during the study period, and none became sedated or
had any nausea or vomiting.
Pharmacokinetics
The tramadol blood concentration-time curves for the
individuals in each group are summarised in Figure 1 and
the mean plasma concentration times are shown in
Figure 2. There were no significant differences in
AUC0-∞ between the healthy subjects and the patients.
The non-compartmental pharmacokinetic parameters
are summarised in Table 2. In both cohorts, absorp-
tion of tramadol after SC administration was rapid.
There were no significant differences in any of the
pharmacokinetic variables (AUC0-∞, p = 0.96; tmax, p = 0.73;
Cmax, p = 0.67; t½, p = 0.96; MRT, p = 0.97). The range of
tmax values was 5–60 minutes in both the healthy subjects
and the patients.
Urinary excretion of tramadol, M1 and M2 metabolites
in both cohorts in our study were measured. They showed
respective mean values of 28.2% tramadol, 4.01% M1 and
1.01% M2 in the urine collected over 10 hours in the healthy
subjects. In the patient cohort, values were 24.3% tramadol,
3.43% M1 and 2.02% M2. The mean M1/tramadol excreted
dose ratios were 0.14 ± 0.12 (range 0.01 to 0.34) for healthy
subjects and 0.17 ± 0.14 (range 0.02 to 0.51) for the patient
cohort. The mean M2/tramadol excreted dose ratios were
0.04 ± 0.03 (range 0.01 to 0.07) for healthy subjects and
0.08 ± 0.09 (range 0.06 to 0.33) for the patient cohort.
Discussion
This study describes the pharmacokinetics of a single
subcutaneous dose of tramadol and shows that there
were no differences in the rates of absorption or drug ex-
posure between healthy subjects and patients. Although the
pharmacokinetic profile of tramadol has previously been
characterised in humans after oral, IM and IV administra-
tion, similar data have not been available for the SC route
[6-9]. While these data are frequently determined in healthy
subjects they cannot always be extrapolated to sick patients,
hence the importance of also documenting pharmacokinet-
ics in this patient cohort [22].
Tramadol is an atypical centrally acting analgesic agent
which acts as both a mu-opioid receptor agonist and in-
hibitor of noradrenaline and serotonin reuptake. It is a
racemic mixture where the (+) enantiomer preferentially
inhibits serotonin reuptake and the (−) enantiomer pref-
erentially inhibits noradrenaline reuptake [23]. Tramadol
is metabolised by O-demethylation to the active M1
and N-demethylation to the inactive M2 metabolites.
Metabolism is dependent on the cytochrome P450 enzymes
CYP2D6 and CYP3A4 [23,24]. M1 displays a 200-fold
higher affinity for the mu-opioid receptor than the par-
ent drug [25]. Tramadol and its metabolites are almost
completely excreted by the kidney [23].
Tramadol is effective in the management of acute pain,
although it may be inadequate for the management of
moderate to severe acute pain if used as the sole analgesic
agent [1,10]. When combined with morphine, tramadol is
opioid-sparing, but the effect is infra-additive [26]. Since
tramadol is less likely to lead to respiratory depression
and reduced gastrointestinal motility compared with pure
opioid agonists at equianalgesic doses, it may be a useful
choice in some patients such as those with respiratory
compromise or obstructive sleep apnea, or those who have
had gastrointestinal surgery [1,23,27,28]. Its effectiveness
in the treatment of acute neuropathic pain may also make
it a worthwhile agent in some patients [29,30].
Pharmacokinetics
While subcutaneous tramadol would not be of interest
in mechanically ventilated critically ill patients where
intravenous sedation and analgesia is a requirement,
subcutaneous pain relief can be useful in spontan-
eously ventilating patients in a high dependency setting
[3,4]. It may avoid the need for IV access and reduce
the incidence of respiratory and gastrointestinal side




Patients n = 15 Healthy subjects
n = 8
Age (years) 43 (20–65)* 25 (19–51)
Gender Male 13 8
Female 2 0
Weight (kg) 75 (72–76) 74 (60–97)
APACHE II score † 7 (2–14) Not applicable
Admission Diagnosis (n) Multi-trauma (10) Not applicable
Orthopedic surgery (1)
Gastrointestinal surgery (4)
All patients and healthy subjects received 50 mg subcutaneous bolus dose of
tramadol. Data are shown as median (range) *p = 0.006 † Acute Physiological
and Chronic Health Evaluation.
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effects when compared to IV administration [2]. How-
ever, the pharmacokinetics of drugs cannot be pre-
sumed to be the same in severely ill patients as in
healthy subjects. Trauma, the perioperative state and
critical illness may affect drug absorption and distribu-
tion due to differences in skin perfusion and cardiac
output. In a similar study investigating the pharmaco-
kinetics of oxycodone after a single SC dose, marked
differences were revealed between healthy subjects and
a similar cohort of patients [22]. The latter showed that
AUC0-∞, Cmax and t½ were all significantly lower in the
patient cohort despite no differences in tmax or MRT.
In contrast, in this study of SC tramadol, no significant
differences were found in AUC0-∞ t½, tmax, Cmax or
MRT between patients and healthy subjects.
The SC pharmacokinetics of absorption of the follow-
ing opioids has previously been reported: morphine in
healthy subjects and older patients; fentanyl in healthy
subjects; and oxycodone in both healthy subjects and
critically ill patients [22,31-33]. The mean tmax values for
tramadol in this study of 20.6 and 23.3 minutes in healthy
subjects and patients, respectively, were comparable to
those reported for oxycodone in both healthy subjects and
critically ill patients (22.1 and 20.5 minutes respectively),
but longer than that reported for fentanyl and morphine in
subjects (both 15 minutes) or morphine in elderly patients
(15.9 minutes).
In comparing the pharmacokinetic parameters of trama-
dol after oral, SC, IV and IM routes of administration in
healthy subjects, our study using the SC route of 50 mg
tramadol showed that the tmax was 20.6 minutes, t½
was 5.2 hours, Cmax was 0.47 mcg/ml and AUC was
175 mcg/ml*min. Previous reports have shown that a
100 mg oral dose of tramadol in healthy subjects gave a tmax
value of 66 minutes, a t½ value of 5.6 hours, a Cmax value
of 0.31 mcg/ml and an AUC value of 160 mcg/ml*min,
Figure 2 Mean plasma concentration times in healthy subjects ( ) and patients ( ). All patients and healthy subjects received a
50 mg subcutaneous bolus dose of tramadol. Data are shown as mean and standard deviation. The time scale is reduced compared to Figure 1
to emphasise the absorption phase.
Table 2 Pharmacokinetic parameters
Parameter/ units Healthy subjects
mean (SD), (n = 8)
Patients mean
(SD), (n = 15)
p value Differences between patients and healthy subjects
Mean Standard error
Cmax (mcg/ml) 0.47 (0.13) 0.44 (0.18) 0.67 −0.032 0.073
AUC∞ (mcg/ml*min) 175 (75) 177 (109) 0.96 2.07 43.6
t½ (min) 310 (147) 306 (164) 0.96 −3.5 69.6
tmax (min) 20.6 (18.8) 23.3 (17.1) 0.73 2.7 7.7
MRT (min) 466 (224) 463 (233) 0.97 −3.4 100.8
All eight healthy subjects and 15 patients received 50 mg tramadol as a subcutaneous bolus injection. The p-value is for a One Factor ANOVA comparing the
cohorts. The mean difference between the patient and healthy groups is shown with its standard error as an indicator of study power.
*represents the unit of AUC as in product of ml and min.
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whilst a single IV dose of 50 mg tramadol gave a t½ value
of 5.5 hours, a Cmax value of 0.35 mcg/ml and an AUC of
93 mcg/ml*min. With a single IM dose of 50 mg tramadol,
the tmax was 45 minutes, t½ was 5.5 hours, Cmax was
0.19 mcg/ml and the AUC was 95 mcg/ml*min [9].
There are limited data on the urinary excretion of
tramadol and its metabolites. In healthy subjects given a
50 mg oral dose of tramadol, the mean values for urinary
excretion over 24 hours (expressed as a percentage of
the dose administered) were tramadol 12%, M1 15%, and
M2 4% [34]. Following a 100 mg dose of oral tramadol,
also given orally to healthy subjects, with urine collected
over 30 hours, the mean values were 16.2% unchanged
tramadol, 11.2% M1, and 1.1% M2 [35]. Similar results
were reported by Rudaz et al. also following administration
of 100 mg oral tramadol to healthy subjects, again with
urine collected over 30 hours: 16% unchanged tramadol,
16% M1 and 2.2% M2 [36]. In our study, respective mean
values were 28.2% tramadol, 4.01% M1 and 1.01% M2 in
the urine collected over 10 hours in the healthy group. In
the patient cohort, values were 24.3% tramadol, 3.43% M1
and 2.02% M2. Since the clearance via the M1 and M2
pathways does not appear to be different between the two
groups (as assessed by the urinary metabolite to tramadol
ratio), this suggests that the CYP2D6 (M1) and CYP3A4
(M2) pathways were not altered in severely ill patients.
The study was designed to avoid pharmacokinetic in-
teractions with other drugs. In the patients fentanyl
was chosen as the “rescue” opioid, delivered by PCA,
for intercurrent pain relief because it is metabolised by
the cytochrome P450 enzyme CYP3A4. CYP3A4 is also
responsible for metabolism of tramadol to M2. However,
fentanyl is only a substrate and not an inducer/inhibitor
of CYP3A4 at therapeutic concentrations. If fentanyl
was competing with tramadol as a substrate for this en-
zyme, the AUC0-∞ results for tramadol would have been
higher in the patients who were receiving fentanyl. Two
of the patients received oral oxycodone during the study
period. Oxycodone is metabolised by CYP3A4 and CYP2D6.
Similarly, oxycodone is only a substrate and not known to
be an inhibitor of CYP2D6, and therefore the results from
these patients were not excluded.
A possible limitation of this study is the mismatching
between the group in terms of age and sex. However
given that no difference was noted in the pharmacokin-
etics between the groups it is unlikely that the results of
the study would have been different if the groups had
been better matched. Based on the paucity of pharmaco-
kinetic data after SC administration of this drug, no a
priori power calculation was performed, which is therefore
one of the limitations of this study. Hence, between-group
differences in some pharmacokinetic parameters, found to
be similar in this study, cannot be confidently excluded as
the study may not have been adequately powered to
demonstrate a difference. Nevertheless, there is no trend
for a difference in any parameter so any possible differ-
ence is likely to be small and may not be clinically rele-
vant. The estimated effect size and its standard error
are given in Table 2 to indicate the study power. More-
over, there may be some patient groups where the
time-course of drug concentrations and effect are clin-
ically different from the patients in the current study.
We chose not to phenotype our subjects for CYP2D6,
because total subject numbers would have been too
small to detect significant differences.
Conclusions
The rate of absorption, time to peak blood concentration,
and the rate of elimination of tramadol following SC
injection were similar in healthy subjects and severely
ill patients. The time to peak absorption was also
similar to pure opioid agonists (morphine, fentanyl
and oxycodone) given by SC injection. As the key
pharmacokinetic parameters governing overall trama-
dol exposure (AUC0-∞) and the peak concentrations
(Cmax, tmax) did not differ, these data show that the same
dosing regimens (dose and frequency of administration)
for SC tramadol administration may be used in both
healthy subjects and in severely ill patients.
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